Cargando…

The Effect of Nintedanib on T-Cell Activation, Subsets and Functions

BACKGROUND: T cells are important regulators of inflammation and, via release of mediators, can contribute to pulmonary fibrosis. Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease (ILD) and chronic fibrosing ILDs with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ubieta, Kenia, Thomas, Matthew James, Wollin, Lutz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954282/ https://www.ncbi.nlm.nih.gov/pubmed/33727792 http://dx.doi.org/10.2147/DDDT.S288369

Ejemplares similares

Effects of Nintedanib in an Animal Model of Liver Fibrosis
por: Wollin, Lutz, et al.
Publicado: (2020)

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
por: Bonella, Francesco, et al.
Publicado: (2015)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing
por: Kato, Kosuke, et al.
Publicado: (2021)

Nintedanib Reduces Muscle Fibrosis and Improves Muscle Function of the Alpha-Sarcoglycan-Deficient Mice
por: Alonso-Pérez, Jorge, et al.
Publicado: (2022)

Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy
por: Piñol-Jurado, Patricia, et al.
Publicado: (2018)

Nintedanib modulates type III collagen turnover in viable precision-cut lung slices from bleomycin-treated rats and patients with pulmonary fibrosis
por: Hesse, Christina, et al.
Publicado: (2022)

Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects
por: Luedtke, Doreen, et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Human microvasculature-on-a chip: anti-neovasculogenic effect of nintedanib in vitro
por: Zeinali, Soheila, et al.
Publicado: (2018)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
por: Nasser, Mouhamad, et al.
Publicado: (2021)

Nintedanib-Induced Colitis Treated Effectively With Budesonide
por: Amini, Afshin, et al.
Publicado: (2020)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Bullous pemphigoid associated with nintedanib
por: Hasson, Amelia M., et al.
Publicado: (2019)

Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
por: Lin, Tong, et al.
Publicado: (2017)

Galectin-3 levels are elevated following nintedanib treatment
por: Shochet, Gali Epstein, et al.
Publicado: (2020)

Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib
por: Bourne, Michael H., et al.
Publicado: (2021)

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
por: Rinciog, C., et al.
Publicado: (2016)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
por: Rinciog, C., et al.
Publicado: (2020)

Nintedanib-Induced Renal Thrombotic Microangiopathy
por: Fujita, Takeshi, et al.
Publicado: (2021)

Focus on Nintedanib in NSCLC and Other Tumors
por: Manzo, Anna, et al.
Publicado: (2016)

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017)

Nintedanib ameliorates animal model of dermatitis
por: Heo, Min-Jeong, et al.
Publicado: (2020)

Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
por: Sato, Seidai, et al.
Publicado: (2017)

The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study
por: Saiphoklang, Narongkorn, et al.
Publicado: (2022)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
por: Westerink, Lotte, et al.
Publicado: (2022)

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
por: Ito, Yoko, et al.
Publicado: (2019)

Nintedanib induces senolytic effect via STAT3 inhibition
por: Cho, Hyun-Ji, et al.
Publicado: (2022)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil
por: Pereira, Carlos Alberto de Castro, et al.
Publicado: (2019)

Development of nintedanib nanosuspension for inhaled treatment of experimental silicosis
por: Andrade da Silva, Luisa Helena, et al.
Publicado: (2022)

Nintedanib in advanced NSCLC: management of adverse events
por: Lemmens, Liesbeth
Publicado: (2016)

The adoption of nintedanib in systemic sclerosis: the SENSCIS study
por: Bruni, Teresa, et al.
Publicado: (2020)

Methylprednisolone/nintedanib: Lack of efficacy: case report
Publicado: (2022)

The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry
por: Štefániková, Marianna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aqpo7l9rbqi1s4hpo4r67l8ldm